News

This is the first research to allow for greater insight into the impacts on providers of a nationwide change to an adalimumab biosimilar.

This study provides further support for the efficacy of this biosimilar, allowing for potential future reduction in costs for patients with IBD.

Preliminary data from the SPARTAN study were presented at ASN Kidney Week 2023, demonstrating sparsentan’s impact on proteinuria and total body water over time.

An analysis of national Canadian data suggest patients receiving either originator or biosimilar infliximab are at a similar risk of the common adverse event.

Most patients with active Crohn’s disease receiving adalimumab biosimilar, HS016, achieved clinical response at weeks 12, 26, and 52.

This new research opens the door for further biological agent use in IBD therapy, helping to expand patients’ array of options when seeking IBD treatment in different countries.

Disparities in nephrology were at the forefront of multiple sessions, presentations, and conversations at ASN Kidney Week 2023.

Analysis shows the rate of use with the originator biologic has decreased from 90% in 2016, to 19% in 2021.

Check out perspective from a pair of ASN Kidney Week 2023 interviews with leading trialists discussing the evolution of cardiovascular-kidney-metabolic syndrome and how pharmacotherapy has propelled the growing recognition.

Trial data support multiple switching between biosimilar and reference product over a 48-week course for the treatment of psoriasis.

Syndesmophyte development was 4 times more probable when patients had a clinical or radiographic description of axial involvement combined with elevated C-reactive protein.

For Lung Cancer Awareness Month, Lungcast speaks with Christy Fischer, a patient who's spent the last 17 years fighting late-stage cancer.

Despite the lack of association with all-cause mortality, this research emphasizes the value of focusing on patients’ psychological well-being due to increased suicide risk among fibromyalgia patients.

Results called attention to a greater risk of hospitalization among patients with CKD who exhibited depressive symptoms, regardless of treatment with dialysis.

Presented at AAO 2023, new data show dual Ang-2/VEGF-A inhibition with faricimab improved pigment epithelial detachment outcomes versus aflibercept.

David Charles, MD, highlights how alternative funding programs, though well-intentioned, can inadvertently erode trust between patients and providers and cause delays in healthcare.

Data presented at ASN Kidney Week 2023 highlighted the patient-reported difficulty of implementing physician-recommended lifestyle changes but noted significant impacts on physical health, mental health, and overall quality of life when done successfully.

In a pooled subcohort analysis of YOSEMITE and RHINE, faricimab showed comparable vision outcomes with fewer injections than aflibercept in DME eyes with baseline BCVA of ≤ 20/50.

This new data indicates both the high mental health burden on this patient population as well as the usefulness of integrated behavioral health care teams in clinics with a pediatric specialty.

Presented at AAO 2023, a retrospective study found no statistically significant difference in retinopathy worsening between GLP-1 RAs and SGLT2 inhibitors.

At ASN Kidney Week 2023, we collected perspectives from 10 key opinion leaders in nephrology on what they see as the most significant news in their specialty from the past year.

Results presented at ASN Kidney Week 2023 highlighted the importance of eGFR and albuminuria measurements for identifying risk of major adverse kidney disease events.

Richard Johnson, MD, discusses the results of a study from ASN Kidney Week 2023 detailing the effects of urate-lowering therapy on blood pressure among patients with gout.

Very few patients switch off a biosimilar due to adverse effects, according to a new study.

Consumers should avoid Dr. Ergin’s SugarMD Advanced Glucose Support due to an increased risk of adverse events including hypoglycemia.

Six-month RIPPLE-1 results show treatment with the IBE-814 intravitreal implant led to CST reduction and BCVA improvement in patients with DME or RVO.

In the PULSAR study, White and Asian participants had similar best corrected visual acuity improvements in the 2 mg aflibercept group.

Presented at AAO 2023, first-time results suggest home OCT may have a significant effect on treatment burden in the management of nAMD.

First-year results from ALTITUDE suggest RGX-314 was well-tolerated and provided meaningful improvements in disease severity at dose levels 1 and 2.

An analysis of data from 26 patients with repeat kidney biopsies in the AURORA program suggests voclosporin (Lupkynis) reduces proteinuria without causing harm in lupus nephritis patients.